While the increase in ERα signaling can be considered an adaptive resistance mechanism, it can also enhance cancer cells’ dependency on estrogen and make them more vulnerable to the combined treatment with PAM inhibitors and anti-estrogens [50]. The gene discussed is ESR1; the disease is cancer.